Safety and effectiveness of bolus insulin aspart in people with type 2 diabetes: a1chieve sub-analysis.

ABSTRACT:

Introduction

This sub-analysis evaluated clinical safety and effectiveness of bolus insulin aspart [with/without oral glucose-lowering drugs (OGLDs)] as the only insulin therapy.

Methods

A1chieve was an international, multicenter, prospective, open-label, non-interventional, observational, 24-week study in people with type 2 diabetes mellitus starting/switching to biphasic insulin aspart 30, insulin detemir or insulin aspart treatment (alone/in combination) in routine clinical practice. This sub-analysis evaluated clinical safety and effectiveness of bolus insulin aspart (±OGLDs) as the only insulin therapy. Data were analyzed for all patients, insulin-experienced and insulin-naive sub-groups, and sub-groups defined by the number of OGLDs prescribed at baseline (no OGLDs, on

SUBMITTER: Randeree H 

PROVIDER: S-EPMC3687096 | biostudies-literature | 2013 Jun

REPOSITORIES: biostudies-literature